SIFI S.p.A. Sold to Faes Farma in €270 Million Acquisition
Deal News | Jun 13, 2025 | Hogan Lovells
Hogan Lovells has advised the founding shareholders and 21 Invest on the sale of SIFI S.p.A., a company specializing in pharmaceutical and medical devices for eye care, to Faes Farma. The transaction valued SIFI at €270 million, in addition to deferred earn-out provisions contingent upon the commercialization and FDA approval of the orphan drug Akantior. The strategic acquisition enhances Faes Farma's market position in the eye care sector, fostering growth and innovation. The transaction involved a team from Hogan Lovells, led by partner Luca Picone, addressing corporate and M&A aspects with notable input from the firm's US offices on regulatory matters.
Sectors
- Pharmaceuticals
- Healthcare Devices
Geography
- Italy – SIFI S.p.A. is based in Italy, contributing to the relevance of this geography.
- Spain – Faes Farma is a Spanish company undertaking the acquisition.
- USA – The transaction involves FDA regulatory matters, which are relevant to the US market.
Industry
- Pharmaceuticals – The acquisition involves a company that specializes in pharmaceutical products, specifically for eye care.
- Healthcare Devices – SIFI S.p.A. also deals in surgical and medical devices, contributing to the healthcare devices industry.
Financials
- €270 million – The enterprise value of SIFI S.p.A. in the transaction.
Participants
| Name | Role | Type | Description |
|---|---|---|---|
| SIFI S.p.A. | Target | Company | A company specializing in pharmaceutical and medical devices for eye care. |
| Faes Farma | Bidding Company | Company | A pharmaceutical company based in Spain, acquiring SIFI S.p.A. |
| 21 Invest | Selling Company | Private Equity | The private equity firm involved in the sale of SIFI S.p.A. |
| Hogan Lovells | Legal Advisor | Company | A law firm advising on the transaction. |